(Adds Actelion declined to comment)
Nov 24 U.S. healthcare company Johnson & Johnson
has approached Swiss biotechnology firm Actelion Ltd
about a potential takeover, Bloomberg reported on
Thursday, citing people it said were familiar with the matter.
The report said that deliberations are still at an early
stage following Johnson & Johnson's initial offer, and Actelion
is working with an adviser to explore options. (bloom.bg/2g8UTe3)
Johnson & Johnson Chief Executive Alex Gorsky said earlier
this year that the company was interested in making deals to
expand its main consumer, medical device, and pharmaceuticals
segments. He noted that in recent years, J&J had derived about
half its revenue from acquired products.
Johnson & Johnson agreed to buy Abbott Laboratories'
eye care business for about $4.33 billion in cash in September.
Actelion shares have risen more than 13 percent this year,
valuing it at about $17 billion.
In October, Actelion raised its earnings guidance for the
third time this year as sales from its new drugs Opsumit and
Uptravi, which treat pulmonary arterial hypertension (PAH), for
the first time surpassed those of Tracleer, its decade-long
mainstay that lost U.S. patent protection last November.
Actelion declined to comment. Johnson & Johnson did not
respond to a request for comment.
(Reporting by Ankit Ajmera in Bengaluru; Editing by Bill Rigby
and Alan Crosby)